calcitriol + infliximab

Calcitriol + infliximab is a hypothetical or investigational combination of two distinct drugs with different mechanisms of action. Calcitriol is the active form of vitamin D3, functioning as a hormone that regulates calcium and phosphate metabolism and exerts immunomodulatory effects. Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor alpha (TNF-α), used primarily to treat autoimmune inflammatory diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis by neutralizing TNF-α activity[3]. While combination therapies involving infliximab are well established—most commonly with immunomodulators like azathioprine—there is no evidence in the provided literature or major clinical guidelines supporting the use of calcitriol in direct combination with infliximab for any approved indication[1][2][6]. The rationale for combining these agents would be to leverage both anti-inflammatory (infliximab) and potential immunoregulatory (calcitriol) effects; however, this specific pairing has not been clinically validated.